Please select the option that best describes you:
Has anyone had experience with the use of IDH inhibitors in high-grade astrocytomas?
The approval for vorasidenib was granted for low-grade astrocytomas, but under certain conditions, it can also be recommended for, for example, anaplastic astrocytomas with an IDH-1 mutation in a tumor board (if the health insurance company approves). How promising is the therapy? How should the difference between Ivosidenib be evaluated (as an individual compassionate use treatment)?
Answer from: Radiation Oncologist at Academic Institution
For patients with grade 3 IDH-mutant glioma, adjuvant therapy (after maximal safe resection) with RT followed by TMZ or PCV is generally considered the standard-of-care for all patients. Institutional practice varies regarding the choice of TMZ or PCV due to an often greater toxicity profile with PC...
Sign in or Register to read more